Final results from QUASAR2, a multicentre, international randomised Phase III trial of capecitabine (cap) +/- bevacizumab (bev) in the adjuvant setting of Stage II/III colorectal cancer (CRC)

Rachel Midgley, Sharon Love, Ian P.M. Tomlinson, Elaine Johnstone, Claire Scudder, Sarah Pearson, Patrick Julier, Enric Domingo, David Church, Francesco Pezzella, J. Hu, Eva Segelov, Andrew Weaver, David J Kerr

Research output: Contribution to conferenceAbstract

Original languageEnglish
Number of pages1
Publication statusPublished - 2014
Externally publishedYes

Cite this